Take a peek at btov’s latest coverage regarding our community of entrepreneurs.
OrCam recently closed its USD 30 million round
As already announced in the editorial, OrCam recently closed its USD 30 million round based on a USD 1 billion pre-money valuation and exceeded the mark to become a unicorn. Read More.
TechTour’s European Venture Contest (EVC) in Dec 2017
On 12th December 2017, our btov colleague, Christian Winkler, had the opportunity to join as jury member for the European Venture Contest (EVC) final. Read More.
CheckYeti founder Stefan Pinggera featured in Deutsche-startups.de
CheckYeti, a portfolio company of Ringier Digital Ventures and btov Private Investors, was interviewed by Deutsche-startups.de. Read More.
IDAGIO successfully raised a EUR 8m Series A
Our portfolio company IDAGIO successfully raised a EUR 8m Series A funding round led by Tengelmann Ventures with significant participation by btov and other existing investors. Read More.
Roche licenses Immatics target for the development of cancer immunotherapies
We are excited to announce that Swiss healthcare company Roche has exercised its option to exclusively license a proprietary immunotherapy target from btov portfolio company Immatics for further development and commercialization in oncology. Read More.
Wine in Black managed its way to profitability
We are proud to announce that the btov portfolio company Wine in Black managed its way to profitability. The Berlin-based online premium wine shipping company was profitable for the first time in October this year. Read More.
Joblift has successfully completed the Series A round
We are pleased to report that the btov portfolio company Joblift has successfully completed the Series A round. Joblift raised EUR 10m in a funding round led by the London/Berlin VC DN Capital. Read More.
We are happy to announce our investment in Whitebox
It also is a pleasure to announce our investment, also out of the investor network, in Whitebox, the Swiss/German Robo-Advisor. You may have heard of Whitebox as the Robo-Advisor with the best financial performance out there. Read More.
We are happy to announce our investment in PriceHubble
We are happy to announce our investment in PriceHubble, out of our private investor network, alongside Helvetia Ventures and exiting investors, in the recently closed Series A round. Read More.
Business news website Quartz featured Electrochaea’s Power-to-Gas technology
In an interesting article about the inability of battery technologies to solve the world's energy-storage problems, the Power-to-Gas technology of btov portfolio company Electrochaea was proposed as an alternative solution. Read More.
black bee founder Dr. Hanna Köpcke wins Digital Female Leader Award
We are happy to share that Dr. Hanna Köpcke, founder and CTO of btov portfolio company Webdata Solutions, was awarded the Digital Female Leader Award in the category IT / Tech. Read More.
Electrochaea receives STEP Award
We are proud to announce that btov portfolio company Electrochaea, the developer of a power-to-gas energy storage solution, has been awarded with the STEP Award in the category Sustainability. Read More.
Joblift now lists more than two million jobs
Joblift now lists more than two million jobs and - for the first time - enables corporate clients to benefit from Joblift's latest machine learning algorithms and big data analysis. Read More.
ottonova sets another major milestone and novelty in Germany
ottonova sets another major milestone and novelty in Germany: since October, patients can receive treatments directly from their bedside with a digital doctor's visit via video consultation. Read More.
GNA Biosolutions reveals new ultrafast PCR platform at Medica
We are excited to announce that our btov portfolio company GNA Biosolutions, a molecular technology company, today launched it's Pharos V8, an ultrafast PCR instrument for in vitro research use and the world's first Laster PCR platform. Read More.
CodeCheck will soon launch a data analytics solution
Our portfolio company CodeCheck will soon launch a real-time data analytics solution based on acquired data from 1.6m users, initiating a new era of market research. Read More.
btov portfolio company BUX has raised EUR 10.6m Series C
We are pleased to announce that btov portfolio company BUX has raised EUR 10.6m Series C funding round in order to undertake ambitious product expansion. Read More.
Immatics receives USD 58M Series E
We are pleased to announce that our btov portfolio company Immatics has raised USD 58M in financing to further develop its T-cell Receptor based immunotherapies. Read More.
Immatics initiates enrollment of patients into a new phase I clinical trial.
Immatics announced that it has initiated enrollment of patients into a phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program. Read More.